Study | Population | Treatment/Duration | SVR12 |
---|---|---|---|
PEARL-II | GT1b treatment-experienced (N = 179) | 3-DAA + RBV, 12 weeks (n = 88) | 97%(85/88) |
3-DAA only, 12 weeks (n = 91) | 100% (91/91) | ||
PEARL-III | GT1b treatment-naive (N = 419) | 3-DAA + RBV, 12 weeks (n = 210) | 99% (209/210) |
3-DAA only, 12 weeks (n = 209) | 99% (207/209) | ||
PEARL-IV | GT1a treatment-naive (N = 305) | 3-DAA + RBV, 12 weeks (n = 100) | 97% (97/100) |
3-DAA only, 12 weeks (n = 205) | 90% (185/205) | ||
TURQUOISE-II | GT1 treatment-naive and treatment-experienced with compensated cirrhosis (N = 380) | 3-DAA + RBV, 12 weeks (n = 208) | 92% (191/208) |
3-DAA + RBV, 24 weeks (n = 172) | 96% (165/172) | ||
SAPPHIRE-I | GT1 treatment-naive (N = 631) | 3-DAA + RBV, 12 weeks (n = 473) | 96% (455/473) |
SAPPHIRE-II | GT1 treatment-experienced (N = 394) | 3-DAA + RBV, 12 weeks (n = 297) | 96% (286/297) |